MicroPort® Presents Argus OCT at the 32nd GW-ICC Entering the Era of Precision PCI

Beijing, China, 1 November 2021 — Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) recently joined the 32nd Great Wall International Congress of Cardiology (GW-ICC) to present the Argus intravascular OCT (Optical Coherence Tomography) endoluminal imaging device (Argus OCT System) for the first time. GW-ICC offered an opportunity for medical professionals in the heart and cardiovascular space to observe and exchange insights, and hold in-depth discussions on cardiovascular innovation.

During the Congress, MicroPort® held a satellite session with the theme of ‘Microtracing for Better Precisions’, in which Prof. Ning Guo from the First Affiliated Hospital of Xi'an Jiaotong University School of Medicine introduced the six key merits of the Argus OCT system, namely purge-free, excellent crossability, easy positioning, clear vision, high resolution, and accurate matching. She further commented that the Argus NOPURGE® purge-free disposable imaging catheter is designed for simplicity, ease of use, stable imaging, and safety through removal of the purge step.

Prof. Ning Guo commented, "As a OCT product, Argus has defined light sensitivity parameters, which enables the device to better detect light signals from human tissues. It is comparable with competing brands in terms of imaging quality, and provides high-resolution images of the inner, middle and outer membranes of the vessel wall. Argus also supports simultaneous coupling with DSA, providing precise guidance by automatically matching intraoperative angiography and OCT images.”

In addition, Prof. Wei Liu, from Beijing Jishuitan Hospital, shared the clinical application of OCT-guided PCI, commenting that due to the absence of a universal standard process for PCI optimization and limited evidence of the clinical benefit of OCT, the application of OCT in practice is still uncommon and inconsistent.

Prof. Wei Liu stated, “The latest OCT-guided PCI process can be simplified into six steps called ‘MLD-MAX’, which focuses on maximizing the minimum lumen area. Having followed the MLD-MAX process, Argus OCT has a proven track record of guiding surgeons in making treatment strategies in real-world clinical events.”

Towards the end of the satellite session, Prof. Bo Xu from Fuwai Hospital of Chinese Academy of Medical Sciences presented the value of OCT evaluation in bioresorbable scaffolds (BRS) implantation and clinical research. There is a significant difference between BRS and traditional metal drug-eluting stents in terms of materials, mechanical properties, and unique degradation process. Compared to arteriography and IVUS (intravascular ultrasound), the measured parameters of OCT are closest to the actual size. This highlights that OCT is an important reference for PSP operations during BRS implantation in real-life clinical settings.

About Shanghai MicroPort Medical (Group) Co., Ltd.

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), is a subsidiary of MicroPort Scientific Corporation (Group) Co., Ltd. (stock code: 00853.HK). Founded in 1998, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians around the world with high-end medical devices and integrated solutions.